Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study by 
  
 University of Groningen
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering
Drugs The CVD-REAL 2 Study
CVD-REAL Investigators Study Grp; Kosiborod, Mikhail; Lam, Carolyn S. P.; Kohsaka, Shun;
Kim, Dae Jung; Karasik, Avraham; Shaw, Jonathan; Tangri, Navdeep; Goh, Su-Yen;
Thuresson, Marcus
Published in:
Journal of the American College of Cardiology
DOI:
10.1016/j.jacc.2018.03.009
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
CVD-REAL Investigators Study Grp (2018). Cardiovascular Events Associated With SGLT-2 Inhibitors
Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study. Journal of the American College of
Cardiology, 71(23), 2628-2639. https://doi.org/10.1016/j.jacc.2018.03.009
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019




J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 7 1 , N O . 2 3 , 2 0 1 8
ª 2 0 1 8 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .Cardiovascular Events Associated
With SGLT-2 Inhibitors Versus Other
Glucose-Lowering Drugs
The CVD-REAL 2 StudyMikhail Kosiborod, MD,a Carolyn S.P. Lam, MBBS, PHD,b,c Shun Kohsaka, MD,d Dae Jung Kim, MD,e
Avraham Karasik, MD,f Jonathan Shaw, MD,g Navdeep Tangri, MD, PHD,h Su-Yen Goh, MD,i Marcus Thuresson, PHD,j
Hungta Chen, PHD,k Filip Surmont, MD,l Niklas Hammar, PHD,m,n Peter Fenici, MD,o









nABACKGROUND Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose
cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data
suggested similar SGLT-2i effects in T2D patients with a broader risk proﬁle, but these studies focused on heart failure
and death and were limited to the United States and Europe.
OBJECTIVES The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus
other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Paciﬁc, the Middle East, and North American regions.
METHODS New users of SGLT-2i and oGLDs were identiﬁed via claims, medical records, and national registries in South
Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each
country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and
stroke were assessed by country and pooled using weighted meta-analysis.
RESULTS After propensity-matching, there were 235,064 episodes of treatment initiation in each group; w27% had
established CV disease. Patient characteristics were well-balanced between groups. Dapagliﬂozin, empagliﬂozin, ipra-
gliﬂozin, canagliﬂozin, tofogliﬂozin, and luseogliﬂozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in
the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51;
95% conﬁdence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p ¼ 0.001), death or HHF
(HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68;
95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups,
including those with and without CV disease.
CONCLUSIONS In this large, internationalstudyofpatientswithT2DfromtheAsiaPaciﬁc, theMiddleEast, andNorthAmerica,
initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics.
(Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614)
(J Am Coll Cardiol 2018;71:2628–39) © 2018 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2018.03.009
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AND ACRONYM S
ACD = all-cause death
ACEi = angiotensin converting
enzyme inhibitor
ARB = angiotensin receptor
blocker
CI = conﬁdence interval
CVD = cardiovascular disease
HHF = hospitalization for heart
failure
HR = hazard ratio
IR = incidence rate
MI = myocardial infarction




T2D = type 2 diabetesC ardiovascular disease (CVD) remains theleading cause of mortality and morbidity inpatients with type 2 diabetes (T2D). The ma-
jority of patients with T2D worldwide reside outside
of the United States and Europe, with the largest
number in the Asia Paciﬁc region, and many more in
the Middle East (1–3). These regions are also experi-
encing the most rapid rise in the prevalence of T2D
(1,2). There may be important differences in patient
characteristics, treatment patterns, and the types of
adverse CVD events experienced by patients in
different regions of the world (e.g., stroke is much
more common in Asia [4]). Yet, the outcomes of pa-
tients with T2D in general, and particularly in relation
to novel drug treatments in regions outside of North
America and Europe, including cardiovascular
events, have not been well described. Recognizing
this large gap in knowledge across Asia, the Asia-
Paciﬁc Cohort Studies Collaboration pooled retrospec-
tive studies from the region and conﬁrmed that T2D
was associated with a 2-fold increase in the risk of
CVD and w67% increase in the risk of all-cause death
(ACD) among Asians, with even greater hazard ratios
(HRs) in younger compared with older people (5).SEE PAGE 2640Recent cardiovascular trials have demonstrated a
signiﬁcant reduction in major adverse cardiovascular
events, death, and hospitalizations for heart failure
(HHF) with sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) in patients with T2D, most of whom had
established CVD (6–8); however, only a minority of
patients across these trials were recruited outside of
the United States and Europe. Our prior large phar-
macoepidemiological study—CVD-REAL (Comparative
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Manuscript received March 5, 2018; accepted March 5, 2018.Users of Sodium-Glucose Cotransporter-2 In-
hibitors)—demonstrated that SGLT-2i are
associated with similar cardiovascular effects
across agents (suggesting a class effect), and in
a much broader population of T2D, including
those with a lower risk proﬁle (9). However,
those initial analyses focused on a limited
number of outcomes (ACD and HHF), and only
included patients from the United States and
Europe.
Large, well-designed comparative effec-
tiveness studies comparing cardiovascular
outcomes with various T2D therapies have
not been performed in the Asia Paciﬁc and
the Middle East. Speciﬁcally, given potential
cardiovascular beneﬁts of SGLT-2i, it is
important to understand the effects associ-
ated with use of these agents in real-world
clinical practice across various world re-
gions, and across a broader range of cardio-
vascular outcomes. Accordingly, using well-
established data sources, we evaluated the relation-
ship between the initiation of SGLT-2i versus initia-
tion of other glucose-lowering drugs (oGLDs) with a
broad range of cardiovascular outcomes in over
400,000 patients from 3 major world regions: Asia
Paciﬁc (South Korea, Japan, Singapore, and
Australia), Middle East (Israel), and North America
(Canada).
METHODS
DATA SOURCES. Deidentiﬁed health records across 6
countries (South Korea, Japan, Singapore, Israel,
Australia, and Canada) were analyzed. In South Ko-
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2630Service was used. The National Health Insurance
Service provides a centralized health insurance
database that provides longitudinal data for 97% of
the Korean population, with linkage to the National
Death Registry (10,11).
In Japan, we used the Medical Data Vision Co.,
Ltd., a hospital-based database containing adminis-
trative claims and laboratory data, linked to the
Diagnostic Procedure Combination (ﬂat-fee payment
system) inpatient hospital payment system, covering
over 10 million patients across the country, corre-
sponding to about 20% of the total population in
Japan. Demographic characteristics including the age
and sex distributions of these patients are known to
be very similar to those of national statistics in Japan
(12–14).
In Singapore, we used the SingHealth Diabetes
Registry, a comprehensive clinical registry covering
the largest public health care group in the nation and
including both inpatient and outpatient data, with
approximately 193,000 unique individuals (15). It is
linked to other data sources (e.g., ﬁnancial) via the
SingHealth Electronic Health Intelligence System.
Patient information is also mapped to outcome data
available from the Singapore Cardiac Data Bank (16), a
national registry collecting epidemiological and clin-
ical information on CVDs and procedures (17). It is a
rich source of national data, with 80% of hospital care
delivered in public institutions. The data are used for
a number of quality reporting purposes and research.
In Israel, the Maccabi Health Management Organi-
zation is the second largest health management or-
ganization, and includes complete medical data for
over 100,000 patients with T2D (18). This compre-
hensive registry covers primary and secondary care,
and both inpatient and outpatient settings, laboratory
tests, and dispensed medications. It has been devel-
oped and validated to monitor major chronic dis-
eases, including diabetes and cardiovascular
outcomes (18–20).
In Australia, the National Diabetes Services Scheme
includes 80% to 90% of all people with diabetes (21).
The National Diabetes Services Scheme has been
linked to the Pharmaceutical Beneﬁts Scheme data-
base and to the National Death Index to provide in-
formation on medication use and vital status,
respectively. The linkages were performed by the
Australian Institute of Health and Welfare using
probabilistic matching techniques, as described else-
where (22).
In Canada, the Manitoba Centre for Health Policy’s
Population Health Research Data Repository is a
comprehensive collection of administrative, registry,
survey, and other data primarily relating to residentsof Manitoba. The Drug Program Information Network
database is an electronic, online, point-of-sale pre-
scription drug database that connects Manitoba
Health and pharmacies in Manitoba (a representative
province in Canada) (23). Information about phar-
maceutical dispensations, prescriptions identiﬁed as
potential drug utilization problems, nonadjudicated
prescriptions, ancillary programs, and nondrug
products is captured in real time for all Manitoba
residents, regardless of insurance coverage or ﬁnal
payer. The Drug Program Information Network data-
base can be linked to other administrative health
databases, including the Manitoba Health Services
Commission database, Vital Statistics databases, and
the Canadian Institute for Health Information–
Discharge Abstract Database via a unique personal
health identiﬁcation number that exists for each
resident of Manitoba. Together, these administrative
health databases capture all prescription medica-
tions, hospitalizations, and physician claims for more
than 98% of residents (24).
PATIENT COHORT. All incident episodes of either an
SGLT-2i or oGLD initiation among patients with T2D
(deﬁned by the standard diagnosis codes [Online
Table 1], except in Australia where this was based
on physician or diabetes nurse educator clinical
diagnosis of T2D), were identiﬁed from each country
starting from the date of ﬁrst prescription or phar-
macy dispensation of an SGLT-2i in each respective
country (start date ranged from December 2013 in
Australia to April 2015 in Israel). Treatment initiation
episodes were deﬁned as prescription/ﬁlling of a
prescription (as initial or add-on therapy) for any
SGLT-2i (canagliﬂozin, dapagliﬂozin, empagliﬂozin,
in all countries; ipragliﬂozin in South Korea and
Japan; and tofogliﬂozin and luseogliﬂozin in Japan)
or oGLD (includes oral or injectable drug classes),
including ﬁxed-dose combinations, with no issued
prescriptions of that medicine class during the pre-
ceding year. Additional inclusion criteria were
age $18 years at the time of the ﬁrst new user
episode, and >1-year data history in the database.
Patients with type 1 or gestational diabetes were
excluded. Patients were followed from index date
(initiation of either SGLT-2i or oGLD) until end of the
index treatment (on-treatment analysis only),
migration/leaving the practice/database, last date of
data collection, outcome date, or censoring date
(ranging from June 2016 in Australia to November
2017 in Singapore).
OUTCOMES. The outcomes included ACD, which was
available in all countries, as well as HHF, composite
of ACD or HHF, myocardial infarction (MI), and
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2631stroke, which were available in all countries except
Australia. Outcomes were deﬁned as primary
discharge diagnosis codes (Online Table 2). Of note, in
Japan and Singapore, for the outcome of ACD, only
information on deaths occurring in-hospital were
available. However, in-hospital deaths represent the
majority of fatal events in those countries (25,26).
STATISTICAL ANALYSIS. The baseline characteris-
tics were analyzed using descriptive statistics. Cate-
gorical variables were described by frequencies and
percentages, and continuous variables using mean 
SD. For continuous variables such as age, the overall
mean across all databases was a summary estimate of
country-speciﬁc means, weighted according to the
number of patients in each respective country. The
percentage of individual agents and their respective
contributions to the overall SGLT-2i exposure time for
SGLT-2i, and the percentage of individual index drug
classes for the oGLD group, were summarized by
country and overall.
For the primary analysis, we pursued an approach
in which all episodes of SGLT-2i and oGLD initiation
were eligible to be included. Consequently, each pa-
tient might have contributed more than 1 episode of
new glucose-lowering medication initiation, for
different drug classes (e.g., SGLT-2i as well as various
classes of oGLDs) and at different time points. Since
this leads to dependence between episodes within a
patient, this dependence was accounted for in the
statistical analyses using robust variance estimator,
which is used for clustered observations (in this case,
with more than 1 drug initiation episode being
potentially clustered within the same patient), and is
a way of statistically adjusting the conﬁdence in-
tervals (CIs) to take this into account (27). Such an
approach was considered most optimal because many
patients might have had initiation of both SGLT-2i
and oGLD during the study period; it maximizes the
ability to ﬁnd a best match for the SGLT-2i and oGLD
treatment initiation episodes, while appropriately
ascribing the SGLT-2i exposure time to the SGLT-2i
group and oGLD exposure time to the oGLD group
for each patient.
A nonparsimonious propensity score for initiating
an SGLT-2i was developed (separately within each
country) and for each individual episode of a new
treatment initiation. All available variables in each
country that may have affected treatment assignment
or outcomes were included in the propensity score
(and are listed in Online Table 3; of note, in Australia,
baseline comorbidity information was not available).
Based on propensity scores, episodes of SGLT-2i
initiation were matched 1:1 with episodes of oGLD
initiation. The propensity matching was assessed byevaluating standardized differences of patient char-
acteristics post-match. A signiﬁcant imbalance was
considered to be present if a >10% standardized dif-
ference was present between the 2 groups after pro-
pensity matching.
Incidence rates for all outcomes were assessed by
treatment group. Only the ﬁrst occurrence of each
outcome was included, and the crude incidence rate
(IR) in each group was calculated as the number of
incident events divided by the total number of
person-years at risk. Time to ﬁrst event for the SGLT-
2i and oGLD groups was compared using Cox pro-
portional hazards models and presented as HR and
95% CI for each outcome separately by country. If
there was an episode of SGLT-2i initiation, and at a
later time point there was an episode of oGLD initia-
tion for the same patient (or vice versa), any outcome
event occurring after the initiation of oGLD would be
accounted for in both treatment groups. To account
for within-subject dependence for multiple episodes
of treatment initiation within a study period, we used
a robust variance estimator in the Cox models, as
mentioned in the previous text (27). The primary
analysis used an intention-to-treat approach, in
which patients were followed from the start of an
index treatment until either occurrence of the ﬁrst
outcome event or the censoring date (whichever is
earlier), regardless of whether the index treatment
was discontinued.
The HRs (95% CIs) for each of the endpoints from
each individual country were then pooled together
for an overall weighted summary (28), in which
random-effects models with inverse variance
weighting for each country were implemented (29).
Forest plots displaying the country-speciﬁc HRs (95%
CIs) along with the pooled overall HR (95% CI) were
produced. Analyses for all outcomes were then
repeated across multiple patient subgroups to
examine whether the associations of SGLT-2i and
oGLD with cardiovascular outcomes differed based on
patient demographics or clinical and treatment char-
acteristics. These pre-speciﬁed subgroup analyses
were adjusted for multiple covariates, including age;
sex; frailty; history of heart failure, MI, and atrial
ﬁbrillation; hypertension (if available); obesity/body
mass index (if available); duration of diabetes (if
available); and use of angiotensin-converting enzyme
inhibitors (ACEis) or angiotensin receptor blockers
(ARBs), b-blockers, Caþ-channel blockers, statins,
loop diuretics, and thiazide diuretics.
To test the stability of the ﬁndings, we performed
several sensitivity analyses. First, the data for the
primary analysis were additionally adjusted for mul-
tiple covariates on top of the propensity-score
FIGURE 1 Flow Ch
14,284
excluded (6%)
oGLD ¼ other glucos
inhibitors.
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2632matching (as stated in the previous text). Second, the
analyses for each outcome were repeated using an on-
treatment approach, in which follow-up was censored
at discontinuation of the index treatment. Third, to
further evaluate the robustness of the patient selec-
tion approach, we performed an additional analysis in
which patients were assigned to the SGLT-2i or oGLD
group based only on the ﬁrst episode of new glucose-
lowering treatment initiation during the study period
(i.e., a patient for whom the ﬁrst new prescription
after the study start date was an SGLT-2i was assigned
to the SGLT-2i group, and a patient for whom the ﬁrst
new prescription was oGLD, to the oGLD group).
Thus, none of the patients in this sensitivity analysis
had any prior oGLD initiation (before initiation of
index agent) during the study inclusion period. Of
note, the beginning of the study inclusion period was
deﬁned as the date on which the ﬁrst SGLT-2i was
introduced in each respective country (and thus
differed across the countries). In this “ﬁrst new-user”
analysis, only 1 episode (rather than multiple epi-
sodes) of treatment initiation was counted for each
patient; speciﬁcally, the ﬁrst episode of glucose-
lowering treatment initiation during the study inclu-
sion period. Following patient selection, develop-
ment of a propensity score for initiating SGLT-2i and
1:1 propensity-matching was performed in the same
way as described for the primary analysis. Fourth,
because only in-hospital deaths were evaluated in
Japan and Singapore, the analyses for ACD were
repeated after excluding the data from Japan andart for All Countries Combined
3,917,551 new user













e-lowering drugs; SGLT-2i ¼ sodium-glucose co-transporter-2Singapore. Finally, because information on baseline
comorbidities was not available (and thus not
included in the propensity model) in Australia, we
repeated the analyses for ACD after excluding the
data from Australia.
Due to the deidentiﬁed nature of patient records,
informed consent was not obtained. Analyses of
deidentiﬁed data were conducted in accordance with
local laws and regulations, and received approvals
from respective scientiﬁc/ethics/data protection
committees. The study was conducted according to
the pre-deﬁned study protocol. Country-speciﬁc
analyses were conducted by independent academic/
statistical groups. The meta-analyses were conducted
by Statisticon and were validated by independent
academic statisticians at St. Luke’s Mid America Heart
Institute.
RESULTS
STUDY POPULATION. A total of 3,917,551 new SGLT-2i
or oGLD initiation episodes from 2,581,980 individ-
ual patients were identiﬁed, of which 249,348 were
SGLT-2i and 3,668,203 were oGLD (Figure 1). Prior to
propensity-matching, patients initiated on SGLT-2i
were younger and had lower rates of chronic kidney
disease, similar rates of cardiovascular comorbidities,
and higher rates of microvascular complications.
The use of statins, ACEis, ARBs, and b-blockers was
greater, and the use of loop diuretics was lower in
patients initiated on SGLT-2i versus oGLD. Patients
initiated on SGLT-2i versus oGLD were more likely to
be on other types of glucose-lowering medications at
baseline prior to matching (Online Table 4).
Following propensity matching, a total of 470,128
new SGLT-2i or oGLD initiation episodes from 447,106
individual patients were identiﬁed, of which 235,064
were in each treatment group (Figure 1). Baseline
characteristics were well-balanced between groups
post-match, overall and by country (Table 1), with
standardized differences for all variables #3%
(Table 1, Online Figure 1). Mean age was 57 years, 45%
were women, and w27% had established CVD. Over-
all, w65% of patients received statins, w62% anti-
hypertensive medications, w54% ACEis/ARBs, and
w74% metformin.
The distribution of speciﬁc SGLT-2i compounds
within the SGLT-2i group and classes of index
medications in the oGLD group are shown in Online
Tables 5 and 6, respectively. In terms of total
exposure time, dapagliﬂozin contributed 75% fol-
lowed by empagliﬂozin with 9%, with other SGLT-2i
ranging from 1% to 8% (Table 2).







Age, yrs (SD) 56.7 (12.0) 56.7 (12.9) 0.4
Women 105,843 (45.0) 106,863 (45.5) 0.9
CV history 59,222 (26.8) 56,576 (25.6) 2.7
Myocardial infarction 7,624 (3.4) 7,479 (3.4) 0.4
Unstable angina 12,480 (5.6) 12,235 (5.5) 0.5
Heart failure 15,151 (6.8) 14,741 (6.7) 0.7
Atrial ﬁbrillation 6,026 (2.7) 5,843 (2.6) 0.5
Stroke 20,983 (9.5) 20,153 (9.1) 1.3
PAD 2,446 (1.1) 2,384 (1.1) 0.3
Microvascular disease 116,370 (52.6) 114,630 (51.8) 1.6
CKD 4,211 (1.9) 4,021 (1.8) 0.6
Frailty (yes)* 14,758 (6.7) 14,912 (6.7) 0.3
Metformin 173,783 (73.9) 175,266 (74.6) 1.4
Sulphonylurea 121,209 (51.6) 119,466 (50.8) 1.5
DPP-4 inhibitors 130,674 (55.6) 128,096 (54.5) 2.2
Thiazolidinedione 30,503 (13.0) 29,573 (12.6) 1.2
GLP-1 receptor agonist 6,163 (2.6) 6,022 (2.6) 0.4
Insulin 46,486 (19.8) 44,480 (18.9) 2.2
Antihypertensive therapy 147,166 (62.6) 145,014 (61.7) 1.9
Loop diuretics 16,451 (7.0) 16,100 (6.8) 0.6
Low-ceiling diuretics 17,608 (7.5) 17,173 (7.3) 0.7
ACE inhibitors 20,199 (8.6) 20,062 (8.5) 0.2
ARBs 109,620 (46.6) 109,347 (46.5) 0.2
Statin therapy 153,694 (65.4) 153,466 (65.3) 0.2
Beta-blockers 44,786 (19.1) 43,947 (18.7) 0.9
Aldosterone antagonists 6,719 (2.9) 6,548 (2.8) 0.4
Index year
2013 741 (1.5) 660 (1.3) 1.4
2014 31,639 (14.0) 32,009 (14.2) 0.5
2015 71,405 (32.3) 71,485 (32.3) 0.1
2016 116,940 (52.8) 115,997 (52.4) 0.9
2017 14,339 (27.0) 14,913 (28.1) 2.4
Values are n (%) unless otherwise stated. *Frailty, hospitalized for >3 consecutive days the last
year (31–35).
ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin receptor blockers; CKD ¼ chronic
kidney disease; CV ¼ cardiovascular; DPP-4 ¼ dipeptidyl peptidase-4; GLP-1 ¼ glucagon-like
peptide-1; oGLD ¼ other glucose-lowering drugs; PAD ¼ peripheral artery disease;
SD ¼ standard deviation; SGLT-2i ¼ sodium-glucose co-transporter-2 inhibitors.
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2633SGLT-2i AND ACD. For the primary analysis, mean
follow-up time was 374 days for the SGLT-2i group
and 392 days for the oGLD group. Mean follow-up
time by treatment group for individual countries
and overall is shown in Online Table 7. Over 493,380
person-years of follow-up, there were 5,216 events, of
which 1,930 occurred in the SGLT-2i group (IR 0.80
per 100 person-years) and 3,286 in the oGLD group (IR
1.30 per 100 person-years; event rate by treatment
group in Online Table 8). Initiation of SGLT-2i versus
oGLD was associated with a lower risk of ACD (ITT
unadjusted approach; pooled HR: 0.51; 95% CI: 0.37 to
0.70; p < 0.001) (Figure 2A). HRs consistently favored
SGLT-2i versus oGLD in each country. Similar results
were observed in the ITT-adjusted and on-treatment
analyses (Online Figure 2A, Online Figure 3A). In the
sensitivity analysis using “ﬁrst new-user design,” the
magnitude of the association between SGLT-2i initi-
ation and lower risk of ACD was attenuated; never-
theless, point estimates continued to strongly favor
SGLT-2i versus oGLD, and remained highly statisti-
cally signiﬁcant (Online Figures 4A and 4F). The re-
sults also remained consistent in the sensitivity
analyses excluding the data from Japan and
Singapore (Online Figure 5) and in a separate sensi-
tivity analysis excluding the data from Australia
(Online Figure 6).
SGLT-2i AND HHF. Over 441,357 person-years of
follow-up, there were 5,997 events, of which 2,646
occurred in the SGLT-2i group (IR 1.23 per 100 person-
years) and 3,351 in the oGLD group (IR 1.48 per 100
person-years; event rate by treatment group in Online
Table 8). Initiation of SGLT-2i versus oGLD was
associated with a lower risk of HHF (ITT, unadjusted
approach; pooled HR: 0.64; 95% CI: 0.50 to 0.82;
p ¼ 0.001) (Figure 2B). HRs consistently favored
SGLT-2i versus oGLD in each country. Similar results
were observed in the ITT, adjusted and on-treatment
analyses (Online Figures 2B and 3B). In the sensitivity
analysis using “ﬁrst new-user design,” the magnitude
of the association between SGLT-2i initiation and
lower risk of HHF was attenuated; nevertheless, point
estimates continued to strongly favor SGLT-2i versus
oGLD, and remained highly statistically signiﬁcant
(Online Figures 4B and 4F).
SGLT-2i AND COMPOSITE OUTCOME OF HHF OR
DEATH. Over 441,357 person-years of follow-up,
there were 9,788 events, of which 4,118 occurred in
the SGLT-2i group (IR 1.91 per 100 person-years) and
5,670 in the oGLD group (IR 2.51 per 100 person-years;
event rate by treatment group in Online Table 8).Initiation of SGLT-2i versus oGLD was associated with
a lower risk of HHF or death (ITT, unadjusted
approach; pooled HR: 0.60; 95% CI: 0.47 to 0.76;
p < 0.001) (Figure 2C). HRs consistently favored
SGLT-2i versus oGLD in each country. Similar results
were observed in the ITT, adjusted and on-treatment
analyses (Online Figures 2C and 3C). In the sensitivity
analysis using “ﬁrst new-user design,” the magnitude
of the association between SGLT-2i initiation and
lower risk of HHF or death was attenuated; never-
theless, point estimates continued to strongly favor
SGLT-2i versus oGLD, and remained highly statisti-
cally signiﬁcant (Online Figures 4C and 4F).
TABLE 2 Composition of SGLT-2i in Terms of Total Exposure Time
South Korea Japan Singapore Israel Canada Australia Total
SGLT-2i 168,322 33,890 1,363 9,736 8,032 13,721 235,064
Dapagliﬂozin 91.3 26.1 68.5 50.9 52.0 80.8 74.7
Empagliﬂozin 4.3 13.6 17.9 49.1 7.7 0.0 9.0
Canagliﬂozin 0.0 10.6 13.7 0.0 40.2 19.2 4.4
Ipragliﬂozin 4.4 29.8 0.0 0.0 0.0 0.0 8.3
Luseogliﬂozin 0.0 6.3 0.0 0.0 0.0 0.0 1.1
Tofogliﬂozin 0.0 13.7 0.0 0.0 0.0 0.0 2.5
Values are %.
SGLT-2i ¼ sodium-glucose co-transporter-2 inhibitors.
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2634SGLT-2i AND MI. Over 443,307 person-years of
follow-up, there were 2,249 events, of which 973
occurred in the SGLT-2i group (IR 0.45 per 100
person-years) and 1,276 in the oGLD group (IR 0.56
per 100 person-years; event rate by treatment group
in Online Table 8). Initiation of SGLT-2i versus oGLD
was associated with a lower risk of MI (ITT, unad-
justed approach; pooled HR: 0.81; 95% CI: 0.74 to
0.88; p < 0.001) (Figure 2D). HRs consistently favored
SGLT-2i versus oGLD in each country. Similar results
were observed in the ITT, adjusted and on-treatment
analyses (Online Figures 2D and 3D). In the sensitivity
analysis using “ﬁrst new-user design,” the magnitude
of the association between SGLT-2i initiation and
lower risk of MI was similar to the primary analysis,
and point estimates continued to favor SGLT-2i
versus oGLD and remained highly statistically sig-
niﬁcant (Online Figures 4D and 4F).
SGLT-2i AND STROKE. Over 440,346 person-years of
follow-up, there were 6,439 events, of which 2,791
occurred in the SGLT-2i group (IR 1.30 per 100
person-years) and 3,648 in the oGLD group (IR 1.62
per 100 person-years; event rate by treatment group
in Online Table 8). Initiation of SGLT-2i versus oGLD
was associated with a lower risk of stroke (ITT, un-
adjusted approach; pooled HR: 0.68; 95% CI: 0.55 to
0.84; p < 0.001) (Figure 2E). HRs consistently
favored SGLT-2i versus oGLD in each country.
Similar results were observed in the ITT, adjusted
and on-treatment analyses (Online Figures 2E
and 3E). In the sensitivity analysis using “ﬁrst
new-user design,” the magnitude of the association
between SGLT-2i initiation and lower risk of stroke
was attenuated; nevertheless, point estimates
continued to favor SGLT-2i versus oGLD and
remained highly statistically signiﬁcant (Online
Figures 4E and 4F).
The summary of the associations between initia-
tion of SGLT-2i versus oGLD across the countries
pooled for all outcomes is presented in Figure 2F.SUBGROUP ANALYSES. In all subgroup analyses, for
all outcomes, no meaningful interactions emerged
with patients’ demographic, clinical, or treatment
characteristics, suggesting that none of these vari-
ables appeared to be effect modiﬁers for the associa-
tion between SGLT-2i and cardiovascular events
(Online Figures 7 to 11). Although a small number of
interactions were nominally signiﬁcant, this should
be interpreted with caution, as the results were based
on very large numbers and were not adjusted for
multiple comparisons.
Importantly, in patients with and without estab-
lished CVD at baseline, SGLT-2i inhibitors were
associated with signiﬁcantly lower risks of death,
HHF, death or HHF, MI, and stroke, with no statisti-
cally signiﬁcant interactions across these 2 subgroups
for any of the outcomes (Figure 3).
DISCUSSION
In this international study incorporating well-
established data sources from clinical practice across
6 countries and 3 major world regions, with >400,000
patients and 490,000 patient-years of follow-up, we
have demonstrated that initiation of SGLT-2i,
compared with oGLD, is associated with signiﬁcantly
lower risk of ACD, heart failure events, MI, and stroke
(Central Illustration). Although there were some dif-
ferences in point estimates across countries for many
outcomes, the directionality of associations was
consistent—despite variable patient characteristics,
health care settings, practice patterns, and speciﬁc
SGLT-2i compounds used. These ﬁndings were stable
in multiple sensitivity analyses. Importantly, the re-
sults were also consistent across various patient
subgroups, including those with and without estab-
lished CVD. These ﬁndings suggest that the cardio-
vascular beneﬁts of SGLT-2i may extend both across
various patient ethnic and racial backgrounds, as well
as across the cardiovascular risk continuum, and
likely represent a class effect.
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Pooled hazard ratios (95% CI) for (A) all-cause death, (B) hospitalization for heart failure, (C) composite of all-cause death or hospitalization for heart failure,
(D) myocardial infarction, (E) stroke, and (F) all 5 outcomes (intent-to-treat, unadjusted analysis). ACD ¼ all-cause death; HHF ¼ hospitalization for heart failure;
other abbreviations as in Figure 1.
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Hazard ratio (95% conﬁdence interval [CI]) for ACD: prior CVD: 0.70 (95% CI: 0.60 to 0.80), no prior CVD: 0.57 (95% CI: 0.43 to 0.75).
ACD ¼ all-cause death; CVD ¼ cardiovascular disease; HHF ¼ hospitalization for heart failure; MI ¼myocardial infarction; other abbreviations
as in Figure 2.
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2636Our data should be considered as complementary
to the other large cardiovascular outcomes trials of
SGLT-2i, including EMPA-REG OUTCOME (BI 10773
[Empagliﬂozin] Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients) and the CANVAS
(Canagliﬂozin Cardiovascular Assessment Study)
Program (6–8). Comparisons of effect sizes between
observational studies (such as CVD-REAL 2) and
clinical trials (such as EMPA-REG OUTCOME and the
CANVAS Program) can be challenging due to the
marked differences in the study design and data
ascertainment methods, as well as the number and
deﬁnitions of events and comparators (placebo vs.
oGLD). In particular, the comparison of the event
rates between the cardiovascular outcomes trials
(CVOTs) and CVD-REAL/CVD-REAL 2 is challenging
given that in EMPA-REG OUTCOME nearly all partic-
ipants had established cardiovascular events, and in
the CANVAS Program the majority of the participants
had established CVD (with 28% of the CANVAS Pro-
gram population being in the “primary prevention”
cohort). In contrast, in CVD-REAL 2, performed in a
population that more closely mirrors the utilization of
SGLT-2i in clinical practice, SGLT-2i were being used
in a broad, low-risk population, where the majority of
patients (w74%) did not have established CVD.
Moreover, there are substantial differences in the
number of events accrued; speciﬁcally, despite
having a shorter follow-up duration and includinglower-risk patients in CVD-REAL 2 (as compared with
EMPA-REG OUTCOME or CANVAS), the number of
ACDs, for example, was considerably larger in our
study (due to a much larger sample size) than in
either of the reported CVOTs (5,216 events in CVD-
REAL 2 vs. 463 events in EMPA-REG OUTCOME and
681 events in the CANVAS Program).
Within the context of these limitations in
comparing the results of various studies, it should be
noted that for the outcome of ACD, the overall event
rates were comparable in patients with and without
established CVD between CVD-REAL 2 and the
CVOTs. The observed magnitude of the effect in
terms of lower risk of ACD associated with SGLT-2i
versus oGLD in the subgroup of patients with estab-
lished CVD is quite similar between the CVD-REAL 2
study (HR: 0.70; 95% CI: 0.60 to 0.80) and EMPA-REG
OUTCOME, and somewhat more pronounced
compared with the CANVAS Program, although the
directionality of the effects are similar; the results are
generally comparable, with overlap in 95% CI.
Although the magnitude of the effect in terms of
lower risk of ACD associated with SGLT-2i versus
oGLD was somewhat more pronounced in the CVD-
REAL 2 study in patients without established CVD,
as compared with the CANVAS primary prevention
cohort, the directionality of the effects was again
similar, and the results generally comparable, with
overlap in 95% CI.
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Kosiborod, M. et al. J Am Coll Cardiol. 2018;71(23):2628–39.
Pooled hazard ratios for the outcomes of all-cause death, hospitalization for heart failure, composite of all-cause death or hospitalization for heart failure, myocardial
infarction, and stroke. ACD ¼ all-cause death; HHF ¼ hospitalization for heart failure; oGLD ¼ other glucose-lowering drugs; SGLT-2i ¼ sodium-glucose co-trans-
porter-2 inhibitors.
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2637Furthermore, the associations with SGLT-2i
observed in regard to heart failure events in our
study were generally similar to those observed in
clinical trials, despite a broader patient population
with a lower risk proﬁle. For the outcomes of MI, our
results were also directionally consistent with those
observed in both EMPA-REG and the CANVAS Pro-
gram, and for the outcome of stroke, our data were
directionally consistent with the CANVAS Program
(6,7). In this regard, it is important to point out that
due to the predominantly Asian patient population in
our study, the number of stroke events was high (in
fact, stroke was the most common cardiovascular
event). Potential limitations of observational data
notwithstanding, these ﬁndings are clinically impor-
tant. Speciﬁcally, the association between SGLT-2i
and lower risk of stroke in our study should offer
additional reassurance with regard to the effects of
SGLT-2i on atherothrombotic events. It is also
important to note that the overall event rates in our
study were fairly low, as would be expected in a
population where >70% of patients did not have
established CVD. However, we were able to collect a
substantial number of events for all outcomes due to
the large number of patients. Since studying such alow-risk population in a randomized clinical trial may
not be feasible, investigations such as CVD-REAL may
provide the only available data of SGLT-2i effects for
very low-risk patients. Generally, therapies that
“work” in higher-risk patients would also be expected
to “work” in lower-risk patients, albeit with impor-
tant differences in absolute risk reductions and
numbers needed to treat. Further information on this
will come from the currently ongoing DECLARE-
TIMI 58 (Multicenter Trial to Evaluate the Effect of
Dapagliﬂozin on the Incidence of Cardiovascular
Events–Thrombolysis In Myocardial Infarction 58)
clinical trial (NCT01730534), which includes a broad
population of patients with T2D (the majority without
established CVD).
Furthermore, the ﬁndings were directionally
consistent across countries, despite differences in
type of SGLT-2i used (e.g., 6 SGLT-2i compounds used
in Japan), suggesting a class effect. Importantly,
these results expand on the data from the original
CVD-REAL report by extending the observations
across a much more geographically and ethnically
diverse patient population, in particular including
populations from the Asia Paciﬁc and Middle East
regions. If further conﬁrmed by the ongoing
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In over 400,000 patients
with type 2 diabetes mellitus in the Asia Paciﬁc, the
Middle East, and North America, initiation of SGLT-2i
versus other glucose-lowering agents was associated
with lower rates of death, heart failure, MI, and
stroke, irrespective of patient characteristics or pres-
ence of established CVD. These observations suggest
that the cardiovascular beneﬁts associated with
SGLT-2i may extend across a broader range of
patients, as deﬁned by ethnic and racial background,
and degree of cardiovascular risk.
TRANSLATIONAL OUTLOOK: Further studies are
necessary to elucidate the mechanisms by which
SGLT-2i may reduce death, heart failure, and possibly
atherothrombotic events in patients with diabetes.
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2638DECLARE-TIMI 58 clinical trial, these ﬁndings would
collectively have substantial implications for clinical
practice, especially as it applies to SGLT-2i use in
lower-risk patients.
STUDY LIMITATIONS. The results of our study should
be considered in the context of several potential
limitations. First, due to the observational nature of
the study, and despite robust statistical techniques,
including propensity-matching and multiple sensi-
tivity analyses, a possibility of residual, unmeasured
confounding cannot be excluded. Speciﬁcally, certain
patient and physician factors may not be adequately
captured even in well-structured and established
datasets. However, all countries included in CVD-
REAL 2 offer universal health coverage; it is, there-
fore, unlikely that economic factors had a large role in
selection of patients for initiation of SGLT-2i versus
oGLD. Second, the issue of potential “immortal time”
bias had previously been raised with regard to large
pharmacoepidemiological analyses such as ours (30).
However, the methods we employed (matching epi-
sodes of new glucose-lowering agent initiation, and
sensitivity analysis that examined only “ﬁrst new-
users”) substantially reduced the possibility of such
bias. In this regard, the magnitude of the association
between SGLT-2i and lower risk across all cardiovas-
cular outcomes was more pronounced in our primary
analysis, and was somewhat attenuated in the most
conservative sensitivity analysis (ﬁrst new-user
design)—however, even in this case, all point esti-
mates still strongly favored SGLT-2i versus oGLD.
Therefore, the clinical interpretation of the results
would be similar, regardless of the methodological
approach that was used. Third, we only had available
mortality data from inpatient settings in Japan and
Singapore; however, most fatal events in these
countries occur in the hospital (25,26), and the results
were directionally similar in other countries, where
capture of the mortality data was more comprehen-
sive. Fourth, we did not have comorbidity informa-
tion in Australia, and were thus unable to include this
information in the propensity score in that country.
However, extensive comorbidity information was
included in all other countries, with results in all
countries being directionally consistent. In addition,
the sensitivity analyses of ACD excluding the data
from Japan and Singapore, and separately excluding
the data from Australia, yielded consistent results.
Fifth, we focused on cardiovascular outcomes
only, and did not examine safety. Finally, despite a
large number of patient-years of follow-up, our
average follow-up time was relatively limited, as
SGLT-2i use in real-world practice is still relativelyrecent; longer-term follow-up will be needed to
evaluate if effects are sustained over time.
CONCLUSIONS
In a large, international study spanning 6 countries
and 3 major world regions, evaluating a broad popu-
lation of patients with T2D from clinical practice, we
found that initiation of SGLT-2i as compared with
oGLD was associated with a signiﬁcantly lower risk of
cardiovascular outcomes, including death, heart fail-
ure, and atherothrombotic events. Collectively, our
results suggest that the cardiovascular beneﬁts of
SGLT-2i may be applicable to a considerably broader
patient population than previously considered. If
further conﬁrmed by the ongoing DECLARE-TIMI 58
trial, which is investigating the efﬁcacy and safety of
dapagliﬂozin in a broad population of patients with
T2D, these ﬁndings could have substantial implica-
tions for clinical practice.
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